XML 53 R42.htm IDEA: XBRL DOCUMENT v3.25.4
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Oct. 31, 2025
Segment Reporting Information [Line Items]      
Revenues  
Research and development expenses 1,102 1,552  
General and administrative expenses 1,614 1,834  
Total operating costs and expenses 2,716 3,386  
Loss from operations (2,716) (3,386)  
Interest income 131 173  
Net loss (2,585) (3,213)  
Total operating expenses 2,716 3,386  
Less non-cash stock-based compensation (796) (1,055)  
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure) 1,920 2,331  
Total assets 15,233   $ 16,080
Cancer Vaccines [Member]      
Segment Reporting Information [Line Items]      
Revenues  
Research and development expenses 673 975  
General and administrative expenses 989 1,152  
Total operating costs and expenses 1,662 2,127  
Loss from operations (1,662) (2,127)  
Interest income 80 109  
Net loss (1,582) (2,018)  
Total operating expenses 1,662 2,127  
Less non-cash stock-based compensation (488) (660)  
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure) 1,174 1,467  
Total assets 9,288   9,604
CAR-T Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Revenues  
Research and development expenses 429 577  
General and administrative expenses 622 663  
Total operating costs and expenses 1,051 1,240  
Loss from operations (1,051) (1,240)  
Interest income 51 63  
Net loss (1,000) (1,177)  
Total operating expenses 1,051 1,240  
Less non-cash stock-based compensation (308) (392)  
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure) 743 848  
Total assets 5,894   6,347
Other [Member]      
Segment Reporting Information [Line Items]      
Revenues  
Research and development expenses  
General and administrative expenses 3 19  
Total operating costs and expenses 3 19  
Loss from operations (3) (19)  
Interest income 1  
Net loss (3) (18)  
Total operating expenses 3 19  
Less non-cash stock-based compensation (3)  
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure) 3 $ 16  
Total assets $ 51   $ 129